Antiretroviral therapy without nucleoside reverse transcriptase inhibitors: dual therapy with darunavir/p and rilpivirine. Safety and efficacy in clinical practice. RIDAR 2
Resumen: INTRODUCTION
The toxicity of conventional antiretroviral treatments (ART) coupled with The toxicity of conventional antiretroviral treatments (ART), coupled with i d biditi i ti t ith HIV h td th h f i i i aging and comorbidities in patients with HIV, have prompted the search for Figure 1 . Study patient population gg new strategies that do not involve the use of nucleoside analogues One of g y p pp new strategies that do not involve the use of nucleoside analogues. One of the available options is dual therapy with darunavir /p (DRV/p) and rilpivirine (RIL) To date no clinical trials have demonstrated the efficacy and safety of this combination, and the available evidence comes only from real - world data. The aim of this study was to evaluate the results of a 48 week course of DRV/p + RIL in clinical practice in Spain
PATIENTS AND METHODS
This was a multicenter, retrospective, observational study conducted in 19 Spanish hospitals. All patients over 18 years of age who began dual therapy with DRV/p + RIL, whether for toxicity or to improve adherence, simplify treatment or prevent complications, between May 2012 and December 2017 were included in the study. Patients with active AIDS, hepatitis B, pregnant women, and those with mutations associated with DRV/p and RIL resistance were excluded. The following data were collected from patients'' clinical records: sociodemographic data, HIV-related data (including history of prior treatments), reason for beginning dual therapy, CD4+ count, and viral load at 24 and 48 weeks after starting treatment. The statistical analysis was performed using the IBM SPSS package (version 22).
Poster [P115]
RESULTS
We included 301 patients; 76.1% were men, and median age was 49 (42-54) years. Viral load was undetectable in 81.4% of patients after 24 weeks of treatment and in 89.2% of patients with available information after 48 weeks of treatment.

Idioma: Inglés
Año: 2018
Publicado en: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 21 (2018), [2 pp]
ISSN: 1758-2652

Originalmente disponible en: Texto completo de la revista

Factor impacto JCR: 5.192 (2018)
Categ. JCR: INFECTIOUS DISEASES rank: 7 / 89 = 0.079 (2018) - Q1 - T1
Categ. JCR: IMMUNOLOGY rank: 31 / 157 = 0.197 (2018) - Q1 - T1

Factor impacto SCIMAGO: 3.053 - Public Health, Environmental and Occupational Health (Q1) - Infectious Diseases (Q1)

Tipo y forma: Congress (Published version)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.


Exportado de SIDERAL (2020-01-17-21:50:47)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Articles



 Record created 2018-12-18, last modified 2020-01-17


Versión publicada:
 PDF
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)